CDK4 and breast cancer: Further analyses of patients pretreated with a CDK4/6 inhibitor in the ongoing Phase III study CAPItello-291 (NCT04305496), which is evaluating combination capivasertib with fulvestrant, will definitively inform PTEN’s role as a therapeutic target in BC.